Gonadotropic pituitary adenomas: Two cases report
Department of Endocrinology, Diabetology and Metabolic Diseases, PCIM Laboratory, FMPM, Cadi Ayyad University, CHU Mohamed VI Marrakech, Morocco.
Case Study
World Journal of Advanced Research and Reviews, 2023, 17(02), 732–734
Article DOI: 10.30574/wjarr.2023.17.2.0297
Publication history:
Received on 08 January 2023; revised on 19 February 2023; accepted on 22 February 2023
Abstract:
The pituitary gonadotropic adenoma is an adenoma developed́ in the gonadotropic cells of the anterior pituitary. It can be secreting releasing in excess in blood and urine; the products of its secretion are gonadostimulines (F.S.H. and L.H.) or non-secreting in this case only histo- cytochemical analysis will be able to allow identification. We report two cases of macroadenoma with LH-FSH immunostaining. Pituitary magnetic resonance imaging revealed a macroadenoma. Transphenoidal surgery was incomplete. Immunohistochemical staining showed that the tumor cells were reactive to LH (70%) and FSH (30%). Control pituitary imaging revealed a residual macroadenoma and deficit replacement was started.
Hormonal testing for all patients with pituitary adenoma should be performed even in the absence of symptoms of hypersecretion. The treatment of gonadotropic adenomas is surgical. Complementary radiotherapy is usually indicated in case of postoperative tumor remnants with an effect on the prevention of recurrence. Medical treatment (dopaminergic agonists, somatostatin analogues, GnRH agonists and antagonists) is disappointing.
Keywords:
Adénome gonadotrope; Immuno-cytochimie; Folliculostimulating hormone (FSH); Luteining hormone (LH)
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0